Abstract:Background: Mitochondrial dysfunction and metabolic abnormalities are acknowledged as significant factors in the onset of neurodegenerative disorders such as Parkinson's disease (PD) and Alzheimer's disease (AD). Our research has demonstrated that the use of combined metabolic activators (CMA) may alleviate metabolic dysfunctions and stimulate mitochondrial metabolism. Therefore, the use of CMA could potentially be an effective therapeutic strategy to slow down or halt the progression of PD and AD. CMAs include substances such as the glutathione precursors (L-serine and N-acetyl cysteine), the NAD+ precursor (nicotinamide riboside), and L-carnitine tartrate. Methods: Here, we tested the effect of two different formulations, including CMA1 (nicotinamide riboside, L-serine, N-acetyl cysteine, L-carnitine tartrate), and CMA2 (nicotinamide, L-serine, N-acetyl cysteine, L-carnitine tartrate), as well as their individual components, on the animal models of AD and PD. We assessed the brain and liver tissues for pathological changes and immunohistochemical markers. Additionally, in the case of PD, we performed behavioral tests and measured responses to apomorphine-induced rotations. Findings: Histological analysis showed that the administration of both CMA1 and CMA2 formulations led to improvements in hyperemia, degeneration, and necrosis in neurons for both AD and PD models. Moreover, the administration of CMA2 showed a superior effect compared to CMA1. This was further corroborated by immunohistochemical data, which indicated a reduction in immunoreactivity in the neurons. Additionally, notable metabolic enhancements in liver tissues were observed using both formulations. In PD rat models, the administration of both formulations positively influenced the behavioral functions of the animals. Interpretation: Our findings suggest that the administration of both CMA1 and CMA2 markedly enhanced metabolic and behavioral outcomes, aligning with neuro-histological observations. These findings underscore the promise of CMA2 administration as an effective therapeutic strategy for enhancing metabolic parameters and cognitive function in AD and PD patients.

What problem does this paper attempt to address?

The paper attempts to address the issues of metabolic abnormalities and mitochondrial dysfunction in neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease. Specifically, the researchers aim to improve the metabolic functions in these diseases by using different combinations of metabolic activators (CMA1 and CMA2), thereby slowing or halting disease progression. ### Background and Issues 1. **Metabolic Abnormalities and Mitochondrial Dysfunction**: - Significant metabolic abnormalities and mitochondrial dysfunction are present in neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease. - These metabolic abnormalities not only affect motor and cognitive functions but also involve key metabolic pathways for brain health. 2. **Role of Metabolic Activators**: - Metabolic activators (such as glutathione precursors, NAD+ precursors, etc.) can improve metabolic functions and stimulate mitochondrial metabolism. - The hypothesis is that using these metabolic activators can effectively improve the metabolic health of neurodegenerative diseases. ### Research Objectives - **Evaluate the Effects of CMA1 and CMA2**: - CMA1 includes nicotinamide riboside, L-serine, N-acetylcysteine, and L-tartrate carnitine. - CMA2 includes nicotinamide, L-serine, N-acetylcysteine, and L-tartrate carnitine. - **Animal Model Experiments**: - Test the effects of CMA1 and CMA2 and their individual components in animal models of Alzheimer's disease and Parkinson's disease. - Evaluate pathological changes and immunohistochemical markers in brain and liver tissues. - Conduct behavioral tests in the Parkinson's disease model and measure the apomorphine-induced rotational response. ### Main Findings - **Improvement in Metabolic Indicators**: - CMA1 and CMA2 significantly reduced plasma triglyceride levels. - L-serine or nicotinamide riboside alone significantly reduced total cholesterol and low-density lipoprotein levels. - CMA2 showed better performance than CMA1 in improving metabolic indicators. - **Pathological Improvement**: - CMA1 and CMA2 significantly alleviated neuronal congestion, degeneration, and necrosis. - Particularly, CMA2 showed more significant effects in reducing neuronal necrosis. - Liver tissues also showed noticeable recovery, especially with the use of CMA2. - **Improvement in Behavioral Functions**: - In the Parkinson's disease model, CMA1 and CMA2 significantly improved the animals' behavioral functions, particularly reducing the number of apomorphine-induced rotations. ### Conclusion - **Efficacy of CMA2**: - The results indicate that CMA2 has significant effects in improving metabolic parameters and cognitive functions, potentially serving as an effective strategy for treating Alzheimer's disease and Parkinson's disease. Through these studies, the authors hope to provide new metabolic intervention methods for the treatment of neurodegenerative diseases, thereby improving the metabolic health and quality of life of patients.

Combined Metabolic Activators with Different NAD+ Precursors Improve Metabolic Functions in the Animal Models of Neurodegenerative Diseases

Combined metabolic activators improve metabolic functions in the animal models of neurodegenerative diseases

NMN Synbiotics: A Multifaceted Therapeutic Approach for Alzheimer’s Disease

Combined Metabolic Activators Improve Cognitive Functions in Alzheimer's Disease Patients: a Randomised, Double-Blinded, Placebo-Controlled Phase-Ii Trial

Combined Metabolic Activators Improves Cognitive Functions in Alzheimer's Disease

Combined Metabolic Activators Improve Cognitive Functions without Altering Motor Scores in Parkinson's Disease

Nicotinamide Forestalls Pathology and Cognitive Decline in Alzheimer Mice: Evidence for Improved Neuronal Bioenergetics and Autophagy Procession

The acute effect of different NAD + precursors included in the combined metabolic activators

Longitudinal metabolomics analysis reveals the acute effect of cysteine and NAC included in the combined metabolic activators

Supplementation with NAD+ Precursors for Treating Alzheimer's Disease: A Metabolic Approach

Modulation of Mitochondrial Complex I Activity Averts Cognitive Decline in Multiple Animal Models of Familial Alzheimer's Disease

Combined Metabolic Activators Decrease Liver Steatosis by Activating Mitochondrial Metabolism in Hamsters Fed with a High-Fat Diet

Effect of Cerebralcare Granule® combined with memantine on Alzheimer's disease

RESTORATION OF AXONAL TRAFFICKING OF MITOCHONDRIA AVERTS COGNITIVE DECLINE IN MOUSE MODELS OF FAMILIAL ALZHEIMER'S DISEASE

P2-183 Regional Cerebral Hypoperfusion of Medial Temporal Lobe in Mild Cognitive Impairment

Aerobic exercise combined with chlorogenic acid exerts neuroprotective effects and reverses cognitive decline in Alzheimer’s disease model mice (APP/PS1) via the SIRT1/ /PGC-1α/PPARγ signaling pathway

Synergic Effects of Berberine and Curcumin on Improving Cognitive Function in an Alzheimer’s Disease Mouse Model

Pantothenate-encapsulated liposomes combined with exercise for effective inhibition of CRM1-mediated PKM2 translocation in Alzheimer's therapy

Mechanistic perspectives on differential mitochondrial-based neuroprotective effects of several carnitine forms in Alzheimer's disease in vitro model

Effect of Alternating Nicotinamide Phosphoribosyltransferase Expression Levels on Mitophagy in Alzheimer's Disease Mouse Models

Therapeutic treatment with the anti-inflammatory drug candidate MW151 may partially reduce memory impairment and normalizes hippocampal metabolic markers in a mouse model of comorbid amyloid and vascular pathology